FM/
Articles/
2607004507
  • Open Access
  • Review

Effects of α- and β-Carotene on Liver Diseases Improvement: A Systematic Review

  • Jinfeng Fu 1,2,3,   
  • Lu Dong 1,2,3,   
  • Jingbo Zhou 4,   
  • Liping Du 2,5,   
  • Juan Wang 2,3,*,   
  • Jihong Huang 1,2,4,6,*

Received: 06 Mar 2026 | Revised: 02 Jul 2026 | Accepted: 03 Jul 2026 | Published: 23 Jul 2026

Abstract

Objectives: Chronic liver disease (CLD) has become a major disease that threatens human health. Oxidative stress (OS) is a major contributor to the deterioration of CLD. α- and β-carotene, naturally occurring micronutrients with biological activities such as anti-oxidant, anti-inflammatory and anti-cancer, have been used to defend against or treat CLD. This systematic review aims to explore the role of α- and β-carotene in the prevention and treatment of CLD. Methods: A comprehensive literature search was undertaken on PubMed, EMBASE, Web of Science and CNKI databases from 1993 to 2021, with a deadline of January 2023, and 16 studies were ultimately included in this review. Result: β-carotene supplementation significantly reduced liver fibrosis (SMD = 39.78, 95% CI [−55.55, −24.01]), while gender and obesity status showed no statistical difference. Dietary α‑carotene intake was not associated with a reduced risk of non-alcoholic fatty liver disease (NAFLD) (SMD = 1.09, 95% CI [0.82, 1.36]). However, the serum carotene measurement group with carotenoid supplementation (MD = −5.79; 95% CI [−109.58, 98.00]) was a trend toward improvement of liver disease. Conclusions: Dietary intake of β-carotene tends to reduce the risk of liver disease, while dietary α-carotene intake was not associated with a reduced risk of liver cancer and NAFLD in obese populations, which inspired us to develop fresh concepts for modifying meals for various populations.

References 

  • 1.

    De Muynck, K.; Vanderborght, B.; Van Vlierberghe, H.; et al. The Gut–Liver Axis in Chronic Liver Disease: A Macrophage Perspective. Cells 2021, 10, 2959. https://doi.org/10.3390/cells10112959.

  • 2.

    Abbas, Z.; Shazi, L. Pattern and profile of chronic liver disease in acute on chronic liver failure. Hepatol. Int. 2015, 9, 366–372. https://doi.org/10.1007/s12072-015-9627-z.

  • 3.

    Mahtab, M.A.; Rahman, S.; Khan, M.; et al. Hepatitis E virus is a leading cause of acute-on-chronic liver disease: Experience from a tertiary centre in Bangladesh. Hepatobiliary Pancreat. Dis. Int. 2009, 8, 50–52.

  • 4.

    Loguercio, C.; Tiso, A.; Cotticelli, G.; et al. Management of chronic liver disease by general practitioners in Southern Italy: Unmet educational needs. Dig. Liver Dis. 2011, 43, 736–741. https://doi.org/10.1016/j.dld.2011.04.013.

  • 5.

    Blachier, M.; Leleu, H.; Peck-Radosavljevic, M.; et al. Roudot-Thoraval F. The burden of liver disease in Europe: A review of available epidemiological data. J. Hepatol. 2013, 58, 593–608. https://doi.org/10.1016/j.jhep.2012.12.005.

  • 6.

    Seen, S. Chronic liver disease and oxidative stress—a narrative review. Expert. Rev. Gastroenterol. Hepatol. 2021, 15, 1021–1035. https://doi.org/10.1080/17474124.2021.1949289.

  • 7.

    Lim, J.K.; Nguyen, M.H.; Kim, W.R.; et al. Prevalence of Chronic Hepatitis B Virus Infection in the United States. Am. J. Gastroenterol. 2020, 115, 1429–1438. https://doi.org/10.14309/ajg.0000000000000651.

  • 8.

    Zang, G.H.; Sun, X.; Sun, Y.F.; et al. Chronic liver diseases and erectile dysfunction. Front. Public Health 2023, 10, 1092353. https://doi.org/10.3389/fpubh.2022.1092353.

  • 9.

    Raju, B.; Andani, A.; Kolhapure, S.; et al. Need for hepatitis A prevention in patients with chronic liver disease in the changing epidemiological setting of India. Hum. Vaccines Immunother. 2021, 17, 1520–1529. https://doi.org/10.1080/21645515.2020.1832408.

  • 10.

    Tanwar, S.; Rhodes, F.; Srivastava, A.; et al. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C. World J. Gastroenterol. 2020, 26, 109–133. https://doi.org/10.3748/wjg.v26.i2.109.

  • 11.

    Aghemo, A.; Alekseeva, O.P.; Angelico, F.; et al. Role of silymarin as antioxidant in clinical management of chronic liver diseases: A narrative review. Ann. Med. 2022, 54, 1548–1560. https://doi.org/10.1080/07853890.2022.2069854.

  • 12.

    Yin, X.; Guo, X.; Liu, Z.; et al. Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease. Int. J. Mol. Sci. 2023, 24, 2844. https://doi.org/10.3390/ijms24032844.

  • 13.

    Asrani, S.K.; Hall, L.; Hagan, M.; et al. Trends in Chronic Liver Disease-Related Hospitalizations: A Population-Based Study. Am. J. Gastroenterol. 2019, 114, 98–106. https://doi.org/10.1038/s41395-018-0365-4.

  • 14.

    Uchida, D.; Takaki, A.; Oyama, A.; et al. Oxidative Stress Management in Chronic Liver Diseases and Hepatocellular Carcinoma. Nutrients 2020, 12, 1576. https://doi.org/10.3390/nu12061576.

  • 15.

    Ezhilarasan, D. Oxidative stress is bane in chronic liver diseases: Clinical and experimental perspective. Arab. J. Gastroenterol. 2018, 19, 56–64. https://doi.org/10.1016/j.ajg.2018.03.002.

  • 16.

    Yilmaz, B.; Sahin, K.; Bilen, H.; et al. Carotenoids and non-alcoholic fatty liver disease. Hepatobil Surg. Nutr. 2015, 4, 161–171. https://doi.org/10.3978/j.issn.2304-3881.2015.01.11.

  • 17.

    Christensen, K.; Lawler, T.; Mares, J. Dietary Carotenoids and Non-Alcoholic Fatty Liver Disease among US Adults, NHANES 2003–2014. Nutrients 2019, 11, 1101. https://doi.org/10.3390/nu11051101.

  • 18.

    Lee, Y.; Hu, S.; Park, Y.-K.; et al. Health benefits of carotenoids: A role of carotenoids in the prevention of non-alcoholic fatty liver disease. Prev. Nutr. Food Sci. 2019, 24, 103–113. https://doi.org/10.3746/pnf.2019.24.2.103.

  • 19.

    Ziegler, R.G.; Colavito, E.A.; Hartge, P.; et al. Importance of alpha-carotene, beta-carotene, and other phytochemicals in the etiology of lung cancer. J. Natl. Cancer Inst. 1996, 88, 612–615. https://doi.org/10.1093/jnci/88.9.612.

  • 20.

    D’Adamo, C.R.; Dawson, V.J.; Ryan, K.A.; et al. The CAPN2/CAPN8 locus on chromosome 1q is associated with variation in serum alpha-carotene concentrations. Lifestyle Genom. 2016, 9, 254–264. https://doi.org/10.1159/000452890.

  • 21.

    Liu, Y.Z.; Yang, C.M.; Chen, J.Y.; et al. Alpha-carotene inhibits metastasis in Lewis lung carcinoma in vitro, and suppresses lung metastasis and tumor growth in combination with taxol in tumor xenografted C57BL/6 mice. J. Nutr. Biochem. 2015, 26, 607–615. https://doi.org/10.1016/j.jnutbio.2014.12.012.

  • 22.

    Chen, H.Y.; Yueh, T.C.; Chen, Y.C.; et al. Antimetastatic Effects of alpha-Carotene and Possible Mechanisms of Action in Human Hepatocarcinoma SK-Hep-1 Cells. J. Agric. Food Chem. 2013, 61, 10368–10376. https://doi.org/10.1021/jf4033393.

  • 23.

    Sluijs, I.; Cadier, E.; Beulens, J.W.J.; et al. Dietary intake of carotenoids and risk of type 2 diabetes. Nutr. Metab. Carbiovasc Dis. 2015, 25, 376–381. https://doi.org/10.1016/j.numecd.2014.12.008.

  • 24.

    Li, C.Y.; Ford, E.S.; Zhao, G.X.; et al. Serum alpha-Carotene Concentrations and Risk of Death Among US Adults The Third National Health and Nutrition Examination Survey Follow-up Study. Arch. Intern. Med. 2011, 171, 507–515. https://doi.org/10.1001/archinternmed.2010.440.

  • 25.

    Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Br. Med. J. 2021, 372, n71. https://doi.org/10.1136/bmj.n71.

  • 26.

    Augusteijn, H.E.M.; van Aert, R.C.M.; van Assen, M. The Effect of Publication Bias on the Q Test and Assessment of Heterogeneity. Psychol. Methods 2019, 24, 116–134. https://doi.org/10.1037/met0000197.

  • 27.

    Leo, M.A.; Rosman, A.S.; Lieber, C.S. Differential depletion of carotenoids and tocopherol in liver disease. Hepatology 1993, 17, 977–986. https://doi.org/10.1002/hep.1840170606.

  • 28.

    Pan, W.H.; Wang, C.Y.; Huang, S.M.; et al. Vitamin A, Vitamin E or beta-carotene status and hepatitis B-related hepatocellular carcinoma. Ann. Epidemiol. 1993, 3, 217–224. https://doi.org/10.1016/1047-2797(93)90022-v.

  • 29.

    Ahmed, S.; Leo, M.A.; Lieber, C.S. Interactions between alcohol and beta-carotene in patients with alcoholic liver disease. Am. J. Clin. Nutr. 1994, 60, 430–436. https://doi.org/10.1093/ajcn/60.3.430.

  • 30.

    Rocchi, E.; Seium, Y.; Camellini, L.; et al. Hepatic tocopherol content in primary hepatocellular carcinoma and liver metastases. Hepatology 1997, 26, 67–72. https://doi.org/10.1002/hep.510260109.

  • 31.

    Yadav, D.; Hertan, H.I.; Schweitzer, P.; et al. Serum and liver micronutrient antioxidants and serum oxidative stress in patients with chronic hepatitis C. Am. J. Gastroenterol. 2002, 97, 2634–2639. https://doi.org/10.1016/S0002-9270(02)04399-X.

  • 32.

    Ruhl, C.E.; Everhart, J.E. Relation of elevated serum alanine aminotransferase activity with iron and antioxidant levels in the United States. Gastroenterology 2003, 124, 1821–1829. https://doi.org/10.1016/S0016-5085(03)00395-0.

  • 33.

    Nishino, A.; Maoka, T.; Yasui, H. Preventive effects of β-cryptoxanthin, a potent antioxidant and provitamin A carotenoid, on lifestyle-related diseases—A central focus on its effects on non-alcoholic fatty liver disease (NAFLD). Antioxidants 2021, 11, 43. https://doi.org/10.3390/antiox11010043.

  • 34.

    Wamutu, S.; Francque, S.; Chatterjee, S.; et al. Effects of vitamin C and beta-carotene pre-treatment on liver damage induced by short-term CCL4 administration in rats. J. Hepatol. 2008, 48, S345. https://doi.org/10.1016/S0168-8278(08)60923-X.

  • 35.

    Chaves, G.V.; Pereira, S.E.; Saboya, C.J.; et al. Non-alcoholic fatty liver disease and its relationship with the nutritional status of vitamin A in individuals with class III obesity. Obes. Surg. 2008, 18, 378–385. https://doi.org/10.1007/s11695-007-9361-2.

  • 36.

    Vardi, N.; Parlakpinar, H.; Cetin, A.; et al. Protective Effect of beta-Carotene on Methotrexate-Induced Oxidative Liver Damage. Toxicol. Pathol. 2010, 38, 592–597. https://doi.org/10.1177/0192623310367806.

  • 37.

    Cui, B.; Liu, S.; Wang, Q.; et al. Effect of β-carotene on immunity function and tumour growth in hepatocellular carcinoma rats. Molecules 2012, 17, 8595–8603. https://doi.org/10.3390/molecules17078595.

  • 38.

    Naik, M.M.; Chudasama, P.; Sodagar, N.R.; et al. Comparative hepatoprotective effect of β-carotene and Liv-52 against paracetamol induced liver toxicity in male and female rats. South. Asian J. Exper Biol. 2012, 2, 103–107.

  • 39.

    Kimura, M.; Mikami, K.; Endo, T.; et al. Association between serum β-carotene-to-retinol ratio and severity of hepatic steatosis in non-alcoholic fatty liver disease in Japan: A cross-sectional study. Nutrition 2020, 79, 110984. https://doi.org/10.1016/j.nut.2020.110984.

  • 40.

    El-Baz, F.K.; Ali, S.I.; Basha, M.; et al. Design and evaluation of bioenhanced oral tablets of Dunaliella salina microalgae for treatment of liver fibrosis. J. Drug Deliv. Sci. Technol. 2020, 59, 101845. https://doi.org/10.1016/j.jddst.2020.101845.

  • 41.

    Hussein, A.M.S.; Fouda, K.; Mehaya, F.M.; et al. Fortified vegetarian milk for prevention of metabolic syndrome in rats: Impact on hepatic and vascular complications. Heliyon. 2020, 6, e04593. https://doi.org/10.1016/j.heliyon.2020.e04593.

  • 42.

    El-Baz, F.K.; Salama, A.; Ali, S.I.; et al. Haematococcus pluvialis Carotenoids Enrich Fractions Ameliorate Liver Fibrosis Induced by Thioacetamide in Rats: Modulation of Metalloproteinase and Its Inhibitor. Biomed. Res. Int. 2021, 2021, 6631415. https://doi.org/10.1155/2021/6631415.

  • 43.

    Sanjeevi, N.; Lipsky, L.M.; Nansel, T.R. Hyperglycemia and Carotenoid Intake Are Associated with Serum Carotenoids in Youth with Type 1 Diabetes. J. Acad. Nutr. Diet. 2019, 119, 1340–1348. https://doi.org/10.1016/j.jand.2019.03.009.

  • 44.

    Qiu, Z.X.; Chen, X.; Geng, T.T.; et al. Associations of Serum Carotenoids With Risk of Cardiovascular Mortality Among Individuals With Type 2 Diabetes: Results From NHANES. Diabetes Care. 2022, 45, 1453–1461. https://doi.org/10.2337/dc21-2371.

  • 45.

    Zhu, X.; Shi, M.S.; Pang, H.; et al. Inverse association of serum carotenoid levels with prevalence of hypertension in the general adult population. Front. Nutr. 2022, 9, 971879. https://doi.org/10.3389/fnut.2022.971879.

  • 46.

    Harari, A.; Coster, A.C.F.; Jenkins, A.; et al. Obesity and Insulin Resistance Are Inversely Associated with Serum and Adipose Tissue Carotenoid Concentrations in Adults. J. Nutr. 2020, 150, 38–46. https://doi.org/10.1093/jn/nxz184.

  • 47.

    Yao, N.; Yan, S.M.; Guo, Y.P.; et al. The association between carotenoids and subjects with overweight or obesity: A systematic review and meta-analysis. Food Funct. 2021, 12, 4768–4782. https://doi.org/10.1039/d1fo00004g.

  • 48.

    Matsumoto, M.; Waki, N.; Suganuma, H.; et al. Association between Biomarkers of Cardiovascular Diseases and the Blood Concentration of Carotenoids among the General Population without Apparent Illness. Nutrients 2020, 12, 2310. https://doi.org/10.3390/nu12082310.

  • 49.

    Lai, G.; Weinstein, S.; Albanes, D.; et al. Association of serum α-tocopherol, β-carotene, and retinol with liver cancer incidence and chronic liver disease mortality. Br. J. Cancer. 2014, 111, 2163–2171. https://doi.org/10.1038/bjc.2014.365.

  • 50.

    Xiao, M.L.; Chen, G.D.; Zeng, F.F.; et al. Higher serum carotenoids associated with improvement of non-alcoholic fatty liver disease in adults: A prospective study. Eur. J. Nutr. 2019, 58, 721–730. https://doi.org/10.1007/s00394-018-1678-1.

  • 51.

    Vitaglione, P.; Morisco, F.; Caporaso, N.; et al. Dietary antioxidant compounds and liver health. Crit. Rev. Food Sci. Nutr. 2004, 44, 575–586. https://doi.org/10.1080/10408690490911701.

  • 52.

    Shih, C.-K.; Chang, J.-H.; Yang, S.-H.; et al. beta-carotene and canthaxanthin alter the pro-oxidation and antioxidation balance in rats fed a high-cholesterol and high-fat diet. Br. J. Nutr. 2008, 99, 59–66. https://doi.org/10.1017/s0007114507781497.

  • 53.

    Latief, U.; Husain, H.; Ahmad, R. beta-Carotene supplementation ameliorates experimental liver fibrogenesis via restoring antioxidant status and hepatic stellate cells activity. J. Funct. Food. 2018, 49, 168–180. https://doi.org/10.1016/j.jff.2018.08.027.

  • 54.

    Ozturk, F.; Gul, M.; Ates, B.; et al. Protective effect of apricot (Prunus armeniaca L.) on hepatic steatosis and damage induced by carbon tetrachloride in Wistar rats. Br. J. Nutr. 2009, 102, 1767–1775. https://doi.org/10.1017/s0007114509991322.

  • 55.

    Akkara, P.J.; Sabina, E.P. A biochemical approach to the anti-inflammatory, antioxidant and antiapoptotic potential of beta-carotene as a protective agent against bromobenzene-induced hepatotoxicity in female Wistar albino rats. J. Appl. Biomed. 2020, 18, 87–95. https://doi.org/10.32725/jab.2020.011.

  • 56.

    Wang, Y.; Lu, J.; Qu, H.; et al. β-Carotene extracted from Blakeslea trispora attenuates oxidative stress, inflammatory, hepatic injury and immune damage induced by copper sulfate in zebrafish (Danio rerio). Comp. Biochem. Physiol. C-Toxicol. Pharmacol. 2022, 258, 109366. http://doi.org/https://doi.org/10.1016/j.cbpc.2022.109366.

  • 57.

    Zhao, Z.L.; Chen, J.; Ci, F.F.; et al. alpha-Carotene: A valuable carotenoid in biological and medical research. J. Sci. Food Agric. 2022, 102, 5606–5617. https://doi.org/10.1002/jsfa.11966.

  • 58.

    Murakoshi, M.; Nishino, H.; Satomi, Y.; et al. Potent preventive action of α-carotene against carcinogenesis: Spontaneous liver carcinogenesis and promoting stage of lung and skin carcinogenesis in mice are suppressed more effectively by α-carotene than by β-carotene. Cancer Res. 1992, 52, 6583–6587.

Share this article:
Download PDF
DOI
10.53941/fm.2026.100007
Issue
Volume 2, Issue 3
How to Cite
Fu, J.; Dong, L.; Zhou, J.; Du, L.; Wang, J.; Huang, J. Effects of α- and β-Carotene on Liver Diseases Improvement: A Systematic Review. Food as Medicine 2026, 2 (3), 7. https://doi.org/10.53941/fm.2026.100007.
RIS
BibTex
Copyright & License
article copyright Image
Copyright (c) 2026 by the authors.